公开(公告)号：US11413344B2

公开(公告)日：2022-08-16

申请号：US16478265

申请日：2018-01-05

Applicant: Pfizer Inc.

Inventor： David Cooper ,  Kathrin Ute Jansen ,  Michael William Pride

IPC: A61K39/00 ,  A61K39/09 ,  A61K39/39

Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 18, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

公开(公告)号：US11135279B2

公开(公告)日：2021-10-05

申请号：US16844060

申请日：2020-04-09

Applicant: Pfizer Inc.

Inventor： David Cooper ,  Kathrin Ute Jansen ,  Michael William Pride

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/09 ,  A61K39/385

Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention therefore relates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said immunogenic compositions.

公开(公告)号：US20210196810A1

公开(公告)日：2021-07-01

申请号：US17194224

申请日：2021-03-06

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/09 ,  A61K47/64

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

公开(公告)号：US20200306357A1

公开(公告)日：2020-10-01

申请号：US16899738

申请日：2020-06-12

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/09 ,  A61K47/64

Abstract: The present invention relates to new immunogenic compositions comprising conjughated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumococcal infections using said novel immunogenic compositions.

公开(公告)号：US10653764B2

公开(公告)日：2020-05-19

申请号：US15542802

申请日：2016-01-05

Applicant: Pfizer Inc.

Inventor： David Cooper ,  Kathrin Ute Jansen ,  Michael William Pride

IPC: A61K39/02 ,  A61K39/116 ,  A61K39/00 ,  A61K39/09 ,  A61K39/385

Abstract: An object of the present invention is to provide immunogenic compositions for protection against S. pneumoniae, in particular against S. pneumoniae serogroup 9, while limiting the number of conjugates. The present invention thereforerelates to new immunogenic compositions for use in pneumococcal vaccines and to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said immunogenic compositions.

公开(公告)号：US10543267B2

公开(公告)日：2020-01-28

申请号：US16196150

申请日：2018-11-20

Applicant: PFIZER INC.

Inventor： Kathrin Ute Jansen ,  Annaliesa Sybil Anderson ,  Judith Absalon ,  Jose Miguel Aste-Amezaga ,  Johannes Frederik Beeslaar ,  David Cooper ,  John Erwin Farley ,  Leah Diane Fletcher ,  Shannon Lea Harris ,  Thomas Richard Jones ,  Isis Kanevsky ,  Lakshmi Khandke ,  Paul Liberator ,  John Lance Perez ,  Lynn Marie Phelan ,  Gary Warren Zlotnick

IPC: A61K39/095 ,  A61K31/7028 ,  A61K47/10 ,  A61K47/18 ,  C07K14/22 ,  C07K16/12 ,  A61K47/26 ,  A61K47/64 ,  A61P31/00

Abstract: In one aspect, the invention relates to a composition including a factor H binding protein (fHBP) and a Neisseria meningitidis non-serogroup B capsular polysaccharide. The invention further relates to uses of a composition that includes fHBP, such as, for example, uses to elicit an immune response against N. meningitidis serogroup B strains and non-serogroup B strains. The compositions and methods described herein are directed to administration in humans, including adults, adolescents, toddlers, and infants.

公开(公告)号：US09492559B2

公开(公告)日：2016-11-15

申请号：US14597488

申请日：2015-01-15

Applicant: Pfizer Inc.

Inventor： Emilio Anthony Emini ,  Wendy Jo Watson ,  Avvari Krishna Prasad ,  Mingming Han ,  Jin-Hwan Kim ,  Jianxin Gu ,  Yu-ying Yang ,  Rajesh Kumar Kainthan ,  David Cooper ,  Michael William Pride ,  Kathrin Ute Jansen

IPC: A61K39/00 ,  A61K39/02 ,  A61K39/09 ,  A61K39/385 ,  A61K47/48

CPC classification number: A61K47/4833 ,  A61K39/092 ,  A61K47/646 ,  A61K2039/6037 ,  A61K2039/70 ,  Y02A50/466

Abstract: The present invention relates to new immunogenic compositions comprising conjugated Streptococcus pneumoniae capsular saccharide antigens (glycoconjugates) and uses thereof. Immunogenic compositions of the present invention will typically comprise at least one glycoconjugate from a S. pneumoniae serotype not found in PREVNAR®, SYNFLORIX® and/or PREVNAR 13®. The invention also relates to vaccination of human subjects, in particular infants and elderly, against pneumoccocal infections using said novel immunogenic compositions.

Abstract translation: 本发明涉及包含结合性肺炎链球菌荚膜糖抗原（糖缀合物）的新的免疫原性组合物及其应用。 本发明的免疫原性组合物通常将包含至少一种来自PREVNAR，SYNFLORIX和/或PREVNAR 13中没有发现的肺炎链球菌血清型的糖缀合物。 本发明还涉及使用所述新型免疫原性组合物对人受试者，特别是婴儿和老年人免疫肺炎球菌感染。